Skip to main content

Table 3 Treatment-related adverse events

From: A bedside to bench study of anti-PD-1, anti-CD40, and anti-CSF1R indicates that more is not necessarily better

N = 13

Related to nivolumab alone

Related to cabiralizumab alone

Related to sotigalimab alone

Related to all

Treatment-Related Adverse Events

Grade 1–2

Grade ≥ 3

Grade 1–2

Grade ≥ 3

Grade 1–2

Grade ≥ 3

Grade 1–2

Grade ≥ 3

n (%)

n (%)

n (%)

n (%)

n (%)

n (%)

n (%)

n (%)

Chills

-

-

-

-

8 (62)

0 (0)

-

-

Fatigue & weakness

1 (8)

0 (0)

-

-

-

-

8 (62)

0 (0)

Periorbital edema

-

-

6 (46)

0 (0)

-

-

-

-

Alanine aminotransferase increase

-

-

-

-

-

-

7 (54)

1 (8)

Aspartate aminotransferase increase

-

-

-

-

-

-

3 (23)

5 (38)

Creatine phosphokinase increase

-

-

2 (15)

4 (31)

-

-

-

-

Fever

-

-

-

-

4 (31)

0 (0)

-

-

Nausea/vomiting

-

-

-

-

3 (23)

0 (0)

-

-

Diarrhea

1 (8)

0 (0)

-

-

-

-

-

-

Headache

-

-

-

-

3 (23)

0 (0)

-

-

Rash—maculopapular

-

-

-

-

-

-

3 (23)

0 (0)

Hypothyroidism

2 (15)

0 (0)

-

-

-

-

-

-

Creatinine increase

-

-

-

-

-

-

2 (15)

0 (0)

Pruritis

-

-

-

-

-

-

1 (8)

0 (0)

Myalgia

-

-

-

-

1 (8)

0 (0)

-

-

Lipase increase

1 (8)

0 (0)

-

-

-

-

-

-

Thrush

1 (8)

0 (0)

-

-

-

-

-

-

Hypotension

-

-

-

-

1 (8)

0 (0)

-

-

Hypoglycemia

-

-

-

-

-

-

0 (0)

1 (8)

Flushing

-

-

-

-

1 (8)

0 (0)

-

-

Edema in limbs

-

-

1 (8)

0 (0)

-

-

-

-

Bilirubin increase

-

-

-

-

-

-

0 (0)

1 (8)

Sinus tachycardia

-

-

-

-

1 (8)

0 (0)

-

-

Anemia

-

-

-

-

-

-

1 (8)

0 (0)

Platelet count decrease

-

-

-

-

-

-

1 (8)*

0 (0)

  1. *attributed to nivolumab and sotigalimab only